Clinical Trials Logo

Clinical Trial Summary

Pars-plana vitrectomy (PPV) is the cornerstone of surgical treatment for eyes with complicated proliferative diabetic retinopathy. Anti-VEGF intravitreal injection before PPV has shown a good effect on surgical outcomes. However, many patients present with co-morbidities that contraindicate the usage of anti-VEGF in the pre-operative period. Thus, cryoapplication, an old therapeutic tool for proliferative diabetic retinopathy may be a good alternative. The investigators present herein a comparative study between peripheral retinal cryoapplication and anti-VEGF before vitrectomy for complicated proliferative diabetic retinopathy.


Clinical Trial Description

Pars-plana vitrectomy (PPV) is the cornerstone of surgical treatment of complicated proliferative diabetic retinopathy allowing the removal of vitreous opacity and releasing tractions from the retina. Surgical outcomes, however, are variable depending on a large array of pre, per, and post-operative conditions. The preoperative anti-VEGF intravitreal injection has shown a good effect on surgical outcomes in patients with vitreous hemorrhage or tractional retinal detachment. However, a great number of patients present with co-morbidities that contraindicate the usage of anti-VEGF in the pre-operative period. Thus, an alternative to this adjunctive therapy is worth investigating. In another hand, cryoapplication, an old therapeutic tool for proliferative diabetic retinopathy had been used in patients with non-clear ocular media with vitreous hemorrhage. The investigators present herein a comparative study between peripheral retinal cryoapplication and anti-VEGF before vitrectomy for complicated proliferative diabetic retinopathy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05514925
Study type Interventional
Source University Hospital Fattouma Bourguiba
Contact Imen Ksiaa, Assoc. Prof.
Phone +21694994234
Email khay.imen@yahoo.fr
Status Recruiting
Phase Phase 4
Start date November 21, 2017
Completion date December 31, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT01921192 - Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Phase 4
Recruiting NCT01044875 - Trial of Yellow 577 nm Laser Versus Green 532 nm Laser for Proliferative Diabetic Retinopathy N/A
Active, not recruiting NCT00993525 - Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy(Inipe Study) Phase 1/Phase 2
Completed NCT01307072 - Compliance to Ophthalmic Follow-up Examinations and Surgical Outcome for Proliferative Diabetic Retinopathy N/A
Completed NCT01758757 - Comparison of Small-gauge Vitrectomy and Conventional Vitrectomy for Proliferative Diabetic Retinopathy N/A
Completed NCT00600236 - HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population Phase 3
Completed NCT05414149 - Efficacy and Safety Comparison of IVR and IVC Before Vitrectomy in Proliferative Diabetic Retinopathy N/A
Completed NCT05408416 - Comparison of Surgery Outcome Between Preoperative IVR and Intraoperative IVR in PPV for PDR N/A
Not yet recruiting NCT04464694 - Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema Phase 4
Not yet recruiting NCT03633266 - Anti-VEGF Instead of Intraoperative PRP in Proliferative Diabetic Retinopathy N/A
Completed NCT03490318 - Effectiveness of Multimodal Imaging for the Evaluation of Retinal Oedema And New vesseLs in Diabetic Retinopathy
Completed NCT01627977 - Association of Lutein, Zeaxanthin and Brilliant Blue in Chromovitrectomy Phase 3
Completed NCT00776763 - Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab Phase 2
Recruiting NCT00563043 - Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment Phase 4
Completed NCT00682240 - Morphological and Functional Retinal Changes Following Retinal Photocoagulation Phase 4
Completed NCT00446381 - Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema) N/A
Completed NCT02879422 - Genetic Markers and Proliferative Diabetic Retinopathy N/A
Enrolling by invitation NCT02911311 - Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy N/A
Completed NCT02858076 - Anti-VEGF vs. Prompt Vitrectomy for VH From PDR Phase 2/Phase 3
Recruiting NCT01737957 - Safety and Efficacy of Low-Fluence PRP for PDR N/A